Questions?

REQUEST A MEDICAL SCIENCE LIAISON (MSL)

Questions?

REQUEST A MEDICAL SCIENCE LIAISON (MSL)

A Selective Mechanism of Action1

UPTRAVI® (selexipag) is a prostacyclin pathway therapy that is structurally distinct from prostacyclin1

Three established 
prostanoid 
receptors in 
the human pulmonary artery2

In animal studies*

UPTRAVI® is the only prostacyclin pathway agent to selectively target the IP receptor5

The only established relaxant prostanoid receptor in the human pulmonary artery2

Learn more about UPTRAVI®

View griphon trial

*The 2022 ESC/ERS Guidelines recommend adding UPTRAVI® for patients without cardiopulmonary comorbidities who are at intermediate-low risk despite receiving ERA/PDE5i therapy. In these patients, switching from a PDE5i to riociguat may be considered. In patients who present as intermediate-high or high risk on oral therapies, also consider adding UPTRAVI® or switching from a PDE5i to riociguat if it is not feasible to add IV or SC prostacyclin analogs.

*Clinical significance in humans is unknown.

GRIPHON=Prostacyclin (PGI2) Receptor Agonist In Pulmonary Arterial HypertensiON; IP=prostacyclin.

References: 1. UPTRAVI® (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2. Norel X. Prostanoid receptors in the human vascular wall. ScientificWorldJournal. 2007;7:1359-1374. 3. Capra V, Bäck M, Angiolillo DJ, et al. Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. J Thromb Haemost. 2014;12(2):126-137. 4. Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010;104(1):9-21. 5. Zeng C, Liu J, Zheng X, et al. Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension. Respir Res. 2023;24(1):263. doi:10.1186/s12931-023-02559-3